Novo Nordisk Soars Past $500B as Weight Loss Drugs Fuel Growth
• Novo Nordisk hits $500 billion market valuation on back of booming sales of weight loss drugs like Wegovy and Ozempic
• Forecasts 29% jump in 2023 profits as supply constraints ease and demand continues to surge
• Weight loss drugs having ripple effects, causing companies like Walmart, PepsiCo, and fast food chains to monitor impact
• Faces new competition in weight loss market from Eli Lilly's newly approved Zepbound drug
• Hit new milestone but stock may be priced to perfection - some analysts see limited upside from current valuation